NZ532065A - Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure - Google Patents

Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Info

Publication number
NZ532065A
NZ532065A NZ532065A NZ53206502A NZ532065A NZ 532065 A NZ532065 A NZ 532065A NZ 532065 A NZ532065 A NZ 532065A NZ 53206502 A NZ53206502 A NZ 53206502A NZ 532065 A NZ532065 A NZ 532065A
Authority
NZ
New Zealand
Prior art keywords
dementia
use according
atomoxetine
disease
treatment
Prior art date
Application number
NZ532065A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Donald Richard Gehlert
David Lee Mckinzie
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ532065A publication Critical patent/NZ532065A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ532065A 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure NZ532065A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
NZ532065A true NZ532065A (en) 2007-03-30

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ532065A NZ532065A (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Country Status (26)

Country Link
US (1) US20050009925A1 (enExample)
EP (1) EP1458368B1 (enExample)
JP (1) JP2005517647A (enExample)
KR (1) KR20040066895A (enExample)
CN (1) CN1713900A (enExample)
AU (1) AU2002352625A1 (enExample)
BR (1) BR0213581A (enExample)
CA (1) CA2467802A1 (enExample)
CO (1) CO5590907A2 (enExample)
CZ (1) CZ2004709A3 (enExample)
DE (1) DE60223718T2 (enExample)
EA (1) EA200400793A1 (enExample)
EC (1) ECSP045145A (enExample)
ES (1) ES2295435T3 (enExample)
HR (1) HRPK20040528B3 (enExample)
HU (1) HUP0402619A3 (enExample)
IL (1) IL161989A0 (enExample)
MX (1) MXPA04005716A (enExample)
MY (1) MY136367A (enExample)
NO (1) NO20042904L (enExample)
NZ (1) NZ532065A (enExample)
PL (1) PL369311A1 (enExample)
SK (1) SK2442004A3 (enExample)
TW (1) TW200300672A (enExample)
WO (1) WO2003049724A1 (enExample)
ZA (1) ZA200404274B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
US20070105960A1 (en) * 2003-08-27 2007-05-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317731A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Hyperhidrosis treatment
WO2011014475A2 (en) * 2009-07-31 2011-02-03 National Taiwan University Treating negative symptoms of schizophrenia associated with defective neuregulin 1
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO2001001973A2 (en) * 1999-07-01 2001-01-11 Pharmacia & Upjohn Company Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1047577B (zh) * 1999-10-13 2005-09-16 辉瑞产品公司 用作一元胺重摄取抑制剂的联芳醚衍生物
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
HUP0402619A3 (en) 2008-04-28
NO20042904L (no) 2004-09-07
TW200300672A (en) 2003-06-16
ES2295435T3 (es) 2008-04-16
IL161989A0 (en) 2005-11-20
CZ2004709A3 (cs) 2004-10-13
CN1713900A (zh) 2005-12-28
DE60223718D1 (de) 2008-01-03
WO2003049724A1 (en) 2003-06-19
AU2002352625A1 (en) 2003-06-23
EP1458368B1 (en) 2007-11-21
US20050009925A1 (en) 2005-01-13
HRPK20040528B3 (en) 2006-03-31
KR20040066895A (ko) 2004-07-27
JP2005517647A (ja) 2005-06-16
HUP0402619A2 (hu) 2005-03-29
CA2467802A1 (en) 2003-06-19
CO5590907A2 (es) 2005-12-30
DE60223718T2 (de) 2008-10-30
SK2442004A3 (en) 2004-12-01
EA200400793A1 (ru) 2004-10-28
ZA200404274B (en) 2005-09-13
MXPA04005716A (es) 2004-12-06
HRP20040528A2 (en) 2004-10-31
ECSP045145A (es) 2004-07-23
EP1458368A1 (en) 2004-09-22
MY136367A (en) 2008-09-30
PL369311A1 (en) 2005-04-18
BR0213581A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
JP2006515628A (ja) ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
AU2019203448A1 (en) Fenfluramine for use in the treatment of dravet syndrome
US20050009925A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
CA2332814C (en) Combination therapy for treatment of refractory depression
CA2525366A1 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20050119248A1 (en) Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US6960577B2 (en) Combination therapy for treatment of refractory depression
JP2003519675A (ja) シブトラミンのラセミ型又は光学的に純粋な代謝産物、それらの調製、それらを含有する組成物及びそれらのドーパミン再取込みインヒビターとしての使用
US20070015763A1 (en) Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
US20080200555A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
JP2022511266A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
US20050119253A1 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN115515590A (zh) 马赛替尼用于治疗多发性硬化患者亚群
CZ20031339A3 (cs) Léčení úzkostných poruch
SK14502000A3 (sk) Kombinácie liekov n. a. r. i. (inhibítorov reaktivácie noradrenalínu), výhodne reboxetínu, a pindololu
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
RU2238084C2 (ru) Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения
JP7556031B2 (ja) 認知症患者の行動心理学的症状の治療
EP4537826A1 (en) Method for treating mental diseases
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
HK40071665B (zh) 在痴呆患者中治疗行为和精神症状
TW202132278A (zh) 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed